NCCN guidelines
Revision as of 16:30, 30 November 2023 by Jainsk1 (talk | contribs) (→Middle East and North Africa)
This page will be a gathering place for the National Comprehensive Cancer Network (NCCN) guidelines that do not clearly fit under a disease-specific page.
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
Miscellaneous
- 2003: Unknown et al. Breast Cancer Risk Reduction Clinical Practice Guidelines in Oncology. PubMed
- 2015: Bevers et al. Breast Cancer Risk Reduction, Version 2.2015. PubMed
- 2003: Unknown et al. Breast Cancer Screening and Diagnosis Clinical Practice Guidelines in Oncology. PubMed
- 2018: Bevers et al. Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. PubMed
Middle East and North Africa
- 2010: Abulkhair et al. Modification and implementation of NCCN guidelines on breast cancer in the Middle East and North Africa region. PubMed
- 2010: Içli et al. Modification and implementation of NCCN guidelines on colon cancer in the Middle East and North Africa region. PubMed
- 2010: Yusuf et al. Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region. PubMed
- 2010: Bazarbachi et al. Modification and implementation of NCCN guidelines on lymphomas in the Middle East and North Africa region. PubMed
- 2010: Jazieh et al. Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. PubMed
- 2010: Shamieh et al. Modification and implementation of NCCN Guidelines on palliative care in the Middle East and North Africa region. PubMed
- 2010: Hassen et al. Modification and implementation of NCCN guidelines on prostate cancer in the Middle East and North Africa region. PubMed